Pàgina inicial > Resultats de la cerca: Simkovic, Martin
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
17 p, 1.2 MB Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study / Munir, Talha (St James's Hospital) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Owen, Carolyn (Tom Baker Cancer Centre) ; Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ; Benjamini, Ohad (Sheba Medical Center) ; Janssens, Ann (UZ Leuven Gasthuisberg) ; Levin, Mark-David (Albert Schweitzer Hospital) ; Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ; Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Stevens, Don (Norton Cancer Institute) ; Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ; Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ; Yagci, Munci (Gazi Universitesi Tip Fakultesi) ; Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ; Qi, Keqin (Janssen Research & Development) ; Qi, Qianya (Janssen Research & Development) ; Parisi, Lori (Janssen Research & Development) ; Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ; Schuier, Natasha (Janssen Research & Development) ; Baeten, Kurt (Janssen Research & Development) ; Howes, Angela (Janssen Research & Development) ; Caces, Donne Bennett (Janssen Research & Development) ; Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ; Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699  
Registre complet - Creative Commons
2.
13 p, 1.6 MB First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab : final analysis of the randomized, phase III iLLUMINATE trial / Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Greil, Richard (Salzburg Cancer Research Institute-CCCIT (Àustria)) ; Demirkan, Fatih (Dokuz Eylul University (Turquía)) ; Tedeschi, Alessandra (Niguarda Ca Granda Hospital (Itàlia)) ; Anz, Bertrand (Tennessee Oncology (Estats Units)) ; Larratt, Loree (University of Alberta Hospital (Canadà)) ; Simkovic, Martin (University Hospital and Medical School Hradec (Txèquia)) ; Novak, Jan (Charles University (Txèquia)) ; Strugov, Vladimir (Almazov National Medical Research Centre (Rússia)) ; Gill, Devinder (Princess Alexandra Hospital) ; Gribben, John G. (Barts Cancer Institute) ; Kwei, Kevin (Pharmacyclics LLC) ; Dai, Sandra (Pharmacyclics LLC) ; Hsu, Emily (Pharmacyclics LLC) ; Dean, James P. (Pharmacyclics LLC) ; Flinn, Ian W. (Sarah Cannon Research Institute) ; Universitat Autònoma de Barcelona
iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. [...]
2022 - 10.3324/haematol.2021.279012
Haematologica, Vol. 107 (january 2022) , p. 2108-2120  
Registre complet - Creative Commons
3.
10 p, 631.8 KB Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL : analysis from the iLLUMINATE study / Greil, Richard (Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg. IIIrd Medical Department Paracelsus Medical University) ; Tedeschi, Alessandra (Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Anz, Bertrand (Tennessee Oncology. Department of Medical Oncology) ; Larratt, Loree (University of Alberta Hospital. Department of Clinical Hematology) ; Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ; Gill, Devinder (Princess Alexandra Hospital. Department of Clinical Hematology) ; Gribben, John G. (Queen Mary University of London, Barts Cancer Institute. Centre for Haemato-Oncology) ; Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ; Wang, Zhengyuan (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Cheung, Leo W. K. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Nguyen, Aaron N. (Pharmacyclics LLC, an AbbVie Company. Translational Medicine) ; Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company. Biostatistics) ; Styles, Lori (Pharmacyclics LLC, an AbbVie Company. Clinical Science) ; Demirkan, Fatih (Dokuz Eylül University. Department of Hematology) ; Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1007/s00277-021-04536-6.
2021 - 10.1007/s00277-021-04536-6
Annals of Hematology, Vol. 100 (may 2021) , p. 1733-1742  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem